Hematologic Cancer

HEMATOLOGIC CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Recommendations From FDA-AACR Workshop to Increase African American Representation in Multiple Myeloma Clinical Trials

A workshop was convened by the US Food and Drug Administration and the American Association for Cancer Research to create recommendations for trial design and later stages of drug development in multiple myeloma.
COVID-19 Vaccination and Imaging Misinterpretation: An Interview With Lacey McIntosh, DO, MPH

Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
Therapeutic Approaches to Multiple Myeloma: An Interview With Ajai Chari, MD

Ajai Chari, MD, of Mount Sinai Hospital in New York City, provides his perspective on the current state of care in multiple myeloma.
American Society of Hematology Releases Updated Guidelines for Treating Newly Diagnosed AML in Older Adults

This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.
Data From the CAPTIVATE Study’s uMRD Cohort Suggest Role for Fixed-Duration Therapy in CLL/SLL [Q&A]

John N. Allan, MD, a lead author of the CAPTIVATE study, discusses the findings from the uMRD cohort and their implications for the CLL/SLL paradigm.

HEMATOLOGIC CANCER NEWS

acute lymphoblastic leukemia

Durable B-ALL Control With Allogeneic Transplant After CAR T-Cell Therapy

April 16, 2021

$FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.$

Nomogram Shows Effect of Pleural Effusion on Myeloma Outcome

April 16, 2021

This triple drug regimen became the first FDA-approved all-oral combination for multiple myeloma in

Prophylactic IVIG Is More Effective in Subgroups of Myeloma

April 14, 2021

While survival rates of pediatric patients with cancer are greatly improved, researchers and clinici

Risk Factors for Pediatric Hemorrhagic Cystitis Following HCT

April 14, 2021

Does the failure of pembrolizumab in multiple myeloma clinical trials imply checkpoint inhibition is

Daratumumab Not Cost-Effective for Multiple Myeloma

April 14, 2021

Next post in Hematologic Cancers

Acute Kidney Injury Seen With Induction Chemotherapy for Acute Myeloid Leukemia